Biggest News Aggregation in the World
📰 Nasdaq Coll News

Nasdaq Coll News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Coll. Real-time updates on events, politics, business and more.

Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) from a strong-buy rating to a buy rating in a report published on Wednesday morning. COLL has been the subject of a number of other reports. Needham & Company LLC reiterated a buy rating and issued a $40.00 price target on shares of Collegium Pharmaceutical […]
Piper Sandler Jefferies Financial Group Collegium Pharmaceutical Inc Everence Capital Management Inc Loomis Sayles Co Summerhaven Investment Management

Collegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) will post its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect Collegium Pharmaceutical to post earnings of $1.37 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can […]
Piper Sandler Needham Company Collegium Pharmaceutical Inc Jefferies Financial Group Collegium Pharmaceutical Company Profile Collegium Pharmaceutical

Values First Advisors Inc. Reduces Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Values First Advisors Inc. lowered its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. Values […]
United States Piper Sandler Scott Dreyer Envestnet Asset Management Inc Citigroup Inc Needham Company

Values First Advisors Inc. Sells 9,642 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Values First Advisors Inc. trimmed its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 22.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,865 shares of the specialty pharmaceutical company’s stock after selling 9,642 shares during the period. […]
United States Scott Dreyer Piper Sandler First Advisors Inc Collegium Pharmaceutical Inc Financial Services Group Inc
Source: wkrb13.com

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $39.00 Consensus Price Target from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year target […]
United States Los Angeles Piper Sandler Scott Dreyer Illinois Municipal Retirement Fund Securities Exchange Commission

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $32.81

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $32.81, but opened at $34.50. Collegium Pharmaceutical shares last traded at $33.46, with a volume of 52,196 shares. Analysts Set New Price Targets Several equities research analysts have issued reports on COLL […]
United States Piper Sandler Joseph Ciaffoni Scott Dreyer Collegium Pharmaceutical Inc Needham Company

StockNews.com Upgrades Collegium Pharmaceutical (NASDAQ:COLL) to Strong-Buy

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Friday. Several other research firms also recently commented on COLL. Truist Financial boosted their price target on shares of Collegium Pharmaceutical from $31.00 to $37.00 and gave […]
Joseph Ciaffoni Piper Sandler Scott Dreyer Collegium Pharmaceutical Company Profile Principal Securities Inc Jefferies Financial Group

Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap Up to $32.81

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $32.81, but opened at $34.50. Collegium Pharmaceutical shares last traded at $33.46, with a volume of 52,196 shares changing hands. Analyst Ratings Changes Several equities analysts have commented on COLL […]
Joseph Ciaffoni Shirleyr Kuhlmann Collegium Pharmaceutical Inc Altshuler Shaham Ltd Tower Group Principal Securities Inc

Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, February 22nd. Analysts expect Collegium Pharmaceutical to post earnings of $1.27 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link. Collegium […]
Scott Dreyer Joseph Ciaffoni Financial Services Group Inc Jefferies Financial Group Altshuler Shaham Ltd Tower Group
Source: wkrb13.com

Needham & Company LLC Increases Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $40.00

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its price objective increased by research analysts at Needham & Company LLC from $36.00 to $40.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price points to a potential […]
United States Shirleyr Kuhlmann Joseph Ciaffoni Envestnet Asset Management Inc Jefferies Financial Group Securities Exchange Commission

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science